DE10003757A1 - Ibuprofen-Wirkstoffzubereitung - Google Patents
Ibuprofen-WirkstoffzubereitungInfo
- Publication number
- DE10003757A1 DE10003757A1 DE10003757A DE10003757A DE10003757A1 DE 10003757 A1 DE10003757 A1 DE 10003757A1 DE 10003757 A DE10003757 A DE 10003757A DE 10003757 A DE10003757 A DE 10003757A DE 10003757 A1 DE10003757 A1 DE 10003757A1
- Authority
- DE
- Germany
- Prior art keywords
- preparation
- ibuprofen
- active ingredient
- weight
- dosage forms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims abstract description 110
- 238000002360 preparation method Methods 0.000 title claims abstract description 107
- 229960001680 ibuprofen Drugs 0.000 title claims abstract description 104
- 239000003814 drug Substances 0.000 title claims description 15
- 229940079593 drug Drugs 0.000 title description 9
- 239000007909 solid dosage form Substances 0.000 claims abstract description 33
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 29
- 239000013543 active substance Substances 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims description 108
- 239000011230 binding agent Substances 0.000 claims description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- 239000002552 dosage form Substances 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 238000003825 pressing Methods 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 9
- 239000006069 physical mixture Substances 0.000 description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 238000005507 spraying Methods 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- -1 Alkaline earth metal salts Chemical class 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003463 adsorbent Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001620634 Roger Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical class C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 2
- 229960000920 dihydrocodeine Drugs 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 239000002706 dry binder Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IHHXIUAEPKVVII-APFIOPMWSA-N (2s)-2,6-diaminohexanoic acid;(2r)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 IHHXIUAEPKVVII-APFIOPMWSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- HEFNNWSXXWATRW-SNVBAGLBSA-N levibuprofen Chemical compound CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-SNVBAGLBSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- 229960004159 pseudoephedrine sulfate Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10003757A DE10003757A1 (de) | 2000-01-28 | 2000-01-28 | Ibuprofen-Wirkstoffzubereitung |
| TW090100451A TWI288641B (en) | 2000-01-28 | 2001-01-09 | Ibuprofen active ingredient preparation |
| DE50105771T DE50105771D1 (de) | 2000-01-28 | 2001-01-19 | Ibuprofen-wirkstoffzubereitung |
| KR1020027009476A KR100742489B1 (ko) | 2000-01-28 | 2001-01-19 | 이부프로펜 함유 활성 성분 제제 |
| CA002398288A CA2398288A1 (en) | 2000-01-28 | 2001-01-19 | Ibuprofen containing active agent preparation |
| RU2002123182/15A RU2300368C2 (ru) | 2000-01-28 | 2001-01-19 | Содержащая ибупрофен композиция |
| EP01902340A EP1250132B1 (de) | 2000-01-28 | 2001-01-19 | Ibuprofen-wirkstoffzubereitung |
| PCT/EP2001/000602 WO2001054683A1 (de) | 2000-01-28 | 2001-01-19 | Ibuprofen-wirkstoffzubereitung |
| HU0204202A HUP0204202A3 (en) | 2000-01-28 | 2001-01-19 | Ibuprofen containing active agent preparation, process for its preparation and pharmaceutical compositions containing it |
| IL15052801A IL150528A0 (en) | 2000-01-28 | 2001-01-19 | Ibuprofen containing active agent preparation |
| CZ20022605A CZ296485B6 (cs) | 2000-01-28 | 2001-01-19 | Prípravek obsahující jako aktivní látku ibuprofen |
| MXPA02007076A MXPA02007076A (es) | 2000-01-28 | 2001-01-19 | Preparacion de ingrediente activo de ibuprofeno. |
| US10/181,459 US20030045580A1 (en) | 2000-01-28 | 2001-01-19 | Ibuprofen containing active agent preparation |
| AT01902340T ATE291908T1 (de) | 2000-01-28 | 2001-01-19 | Ibuprofen-wirkstoffzubereitung |
| JP2001555661A JP2003525223A (ja) | 2000-01-28 | 2001-01-19 | イブプロフェンを含有する活性成分製剤 |
| AU30197/01A AU784128B2 (en) | 2000-01-28 | 2001-01-19 | Ibuprofen containing active agent preparation |
| CNB018042325A CN1277535C (zh) | 2000-01-28 | 2001-01-19 | 布洛芬活性成分制剂 |
| ES01902340T ES2239119T3 (es) | 2000-01-28 | 2001-01-19 | Preparacion de principio activo de ibuprofeno. |
| BR0107899-2A BR0107899A (pt) | 2000-01-28 | 2001-01-19 | Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida |
| IL150528A IL150528A (en) | 2000-01-28 | 2002-07-02 | An active ingredient preparation containing ibuprofen |
| NO20023551A NO20023551D0 (no) | 2000-01-28 | 2002-07-25 | Ibuprofen-inneholdende aktivt middel-preparat |
| ZA200206833A ZA200206833B (en) | 2000-01-28 | 2002-08-27 | Ibuprofen containing active agent preparation. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10003757A DE10003757A1 (de) | 2000-01-28 | 2000-01-28 | Ibuprofen-Wirkstoffzubereitung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10003757A1 true DE10003757A1 (de) | 2001-08-02 |
Family
ID=7629069
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10003757A Withdrawn DE10003757A1 (de) | 2000-01-28 | 2000-01-28 | Ibuprofen-Wirkstoffzubereitung |
| DE50105771T Expired - Fee Related DE50105771D1 (de) | 2000-01-28 | 2001-01-19 | Ibuprofen-wirkstoffzubereitung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50105771T Expired - Fee Related DE50105771D1 (de) | 2000-01-28 | 2001-01-19 | Ibuprofen-wirkstoffzubereitung |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20030045580A1 (ru) |
| EP (1) | EP1250132B1 (ru) |
| JP (1) | JP2003525223A (ru) |
| KR (1) | KR100742489B1 (ru) |
| CN (1) | CN1277535C (ru) |
| AT (1) | ATE291908T1 (ru) |
| AU (1) | AU784128B2 (ru) |
| BR (1) | BR0107899A (ru) |
| CA (1) | CA2398288A1 (ru) |
| CZ (1) | CZ296485B6 (ru) |
| DE (2) | DE10003757A1 (ru) |
| ES (1) | ES2239119T3 (ru) |
| HU (1) | HUP0204202A3 (ru) |
| IL (2) | IL150528A0 (ru) |
| MX (1) | MXPA02007076A (ru) |
| NO (1) | NO20023551D0 (ru) |
| RU (1) | RU2300368C2 (ru) |
| TW (1) | TWI288641B (ru) |
| WO (1) | WO2001054683A1 (ru) |
| ZA (1) | ZA200206833B (ru) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008069938A2 (en) * | 2006-12-04 | 2008-06-12 | Scolr Pharma, Inc. | Method of forming a tablet comprising pre-blend of ibupropen and silicon dioxide |
| CN101588793B (zh) * | 2006-12-04 | 2012-12-19 | 斯科尔医药公司 | 包括预混合布洛芬和二氧化硅的形成片剂的方法 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0209265D0 (en) * | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| JP5248733B2 (ja) * | 2003-11-28 | 2013-07-31 | エスエス製薬株式会社 | 揮散防止型固形製剤およびその製造方法 |
| US20060068009A1 (en) * | 2004-09-30 | 2006-03-30 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
| BRPI0503756A (pt) * | 2005-09-06 | 2007-05-15 | Gold Nutrition Pesquisa Desenv | método de processamento de soja pelo uso de enzima especìfica, pó de soja processada e lìquido de soja processada |
| ATE539747T1 (de) | 2006-07-18 | 2012-01-15 | Horizon Therapeutics Inc | Verfahren und medikamente zur verabreichung von ibuprofen |
| CN101646461A (zh) * | 2007-03-13 | 2010-02-10 | 大日本住友制药株式会社 | 口腔崩解片 |
| CN101829064B (zh) * | 2010-04-27 | 2012-04-25 | 海南新中正制药有限公司 | 右旋布洛芬颗粒及其制备方法 |
| WO2011141490A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
| MX340188B (es) | 2010-05-10 | 2016-06-30 | Euro-Celtique S A * | Elaboracion de granulos sin activos y tabletas que comprenden los mismos. |
| JP2010189443A (ja) * | 2010-06-07 | 2010-09-02 | Ss Pharmaceut Co Ltd | 揮散防止型固形製剤およびその製造方法 |
| CN102988322B (zh) * | 2012-12-26 | 2014-09-03 | 合肥科大生物技术有限公司 | 一种精氨酸布洛芬片剂及其制备方法 |
| US9615595B2 (en) | 2013-03-05 | 2017-04-11 | Mera Technology International Inc. | Method and apparatus for wasteless homogenized soybean beverage production |
| AU2014350135B2 (en) | 2013-11-13 | 2017-08-31 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
| WO2019072877A1 (en) * | 2017-10-10 | 2019-04-18 | Capsugel Belgium Nv | GETTING MULTIPARTICULAR COMPOSITIONS |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4609675A (en) * | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
| US4980375A (en) * | 1987-07-10 | 1990-12-25 | Sterling Drug Inc. | Onset-hastened/enhanced antipyretic response |
| US4911921A (en) * | 1989-02-02 | 1990-03-27 | Mallinckrodt, Inc. | High ibuprofen content granulations |
| US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| HUT59653A (en) * | 1990-11-15 | 1992-06-29 | Puetter Medice Chem Pharm | Process for producing complexes containing s/+/-phenyl-alcanoic acids and alpha-hydroxy-alcanoic acids and pharmaceutical compositions containing them as active components |
| GB9119052D0 (en) | 1991-09-06 | 1991-10-23 | Boots Co Plc | Pharmaceutical compositions |
| US5191114A (en) * | 1991-10-09 | 1993-03-02 | Sage Pharmaceuticals, Inc. | Process for enhancing the flow characteristics of ibuprofen |
| US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
| IT1270239B (it) * | 1994-06-17 | 1997-04-29 | Zambon Spa | Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo |
| US5534263A (en) * | 1995-02-24 | 1996-07-09 | Alza Corporation | Active agent dosage form comprising a matrix and at least two insoluble bands |
| US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| US5780055A (en) * | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
| US5904937A (en) * | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
-
2000
- 2000-01-28 DE DE10003757A patent/DE10003757A1/de not_active Withdrawn
-
2001
- 2001-01-09 TW TW090100451A patent/TWI288641B/zh not_active IP Right Cessation
- 2001-01-19 CZ CZ20022605A patent/CZ296485B6/cs not_active IP Right Cessation
- 2001-01-19 MX MXPA02007076A patent/MXPA02007076A/es active IP Right Grant
- 2001-01-19 BR BR0107899-2A patent/BR0107899A/pt not_active Application Discontinuation
- 2001-01-19 EP EP01902340A patent/EP1250132B1/de not_active Expired - Lifetime
- 2001-01-19 US US10/181,459 patent/US20030045580A1/en not_active Abandoned
- 2001-01-19 ES ES01902340T patent/ES2239119T3/es not_active Expired - Lifetime
- 2001-01-19 DE DE50105771T patent/DE50105771D1/de not_active Expired - Fee Related
- 2001-01-19 AT AT01902340T patent/ATE291908T1/de not_active IP Right Cessation
- 2001-01-19 CN CNB018042325A patent/CN1277535C/zh not_active Expired - Fee Related
- 2001-01-19 JP JP2001555661A patent/JP2003525223A/ja not_active Withdrawn
- 2001-01-19 AU AU30197/01A patent/AU784128B2/en not_active Ceased
- 2001-01-19 IL IL15052801A patent/IL150528A0/xx active IP Right Grant
- 2001-01-19 HU HU0204202A patent/HUP0204202A3/hu unknown
- 2001-01-19 RU RU2002123182/15A patent/RU2300368C2/ru not_active IP Right Cessation
- 2001-01-19 CA CA002398288A patent/CA2398288A1/en not_active Abandoned
- 2001-01-19 KR KR1020027009476A patent/KR100742489B1/ko not_active IP Right Cessation
- 2001-01-19 WO PCT/EP2001/000602 patent/WO2001054683A1/de active IP Right Grant
-
2002
- 2002-07-02 IL IL150528A patent/IL150528A/en not_active IP Right Cessation
- 2002-07-25 NO NO20023551A patent/NO20023551D0/no not_active Application Discontinuation
- 2002-08-27 ZA ZA200206833A patent/ZA200206833B/en unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9028869B2 (en) | 2004-09-30 | 2015-05-12 | Shasun Pharmaceuticals Limited | Modified release ibuprofen dosage form |
| US9730895B2 (en) | 2004-09-30 | 2017-08-15 | Shasun Pharmaceuticals Limited | Method for providing modified release of ibuprofen |
| WO2008069938A2 (en) * | 2006-12-04 | 2008-06-12 | Scolr Pharma, Inc. | Method of forming a tablet comprising pre-blend of ibupropen and silicon dioxide |
| WO2008069938A3 (en) * | 2006-12-04 | 2008-10-09 | Scolr Pharma Inc | Method of forming a tablet comprising pre-blend of ibupropen and silicon dioxide |
| US7749537B2 (en) | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
| CN101588793B (zh) * | 2006-12-04 | 2012-12-19 | 斯科尔医药公司 | 包括预混合布洛芬和二氧化硅的形成片剂的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI288641B (en) | 2007-10-21 |
| ATE291908T1 (de) | 2005-04-15 |
| HUP0204202A3 (en) | 2003-04-28 |
| DE50105771D1 (de) | 2005-05-04 |
| WO2001054683A1 (de) | 2001-08-02 |
| HUP0204202A2 (hu) | 2003-03-28 |
| IL150528A (en) | 2007-06-17 |
| EP1250132A1 (de) | 2002-10-23 |
| KR20020069368A (ko) | 2002-08-30 |
| IL150528A0 (en) | 2003-02-12 |
| NO20023551L (no) | 2002-07-25 |
| CN1400896A (zh) | 2003-03-05 |
| RU2300368C2 (ru) | 2007-06-10 |
| AU784128B2 (en) | 2006-02-09 |
| RU2002123182A (ru) | 2004-03-20 |
| ZA200206833B (en) | 2003-08-27 |
| BR0107899A (pt) | 2002-11-05 |
| US20030045580A1 (en) | 2003-03-06 |
| ES2239119T3 (es) | 2005-09-16 |
| KR100742489B1 (ko) | 2007-07-24 |
| MXPA02007076A (es) | 2003-03-27 |
| NO20023551D0 (no) | 2002-07-25 |
| CZ20022605A3 (cs) | 2003-02-12 |
| AU3019701A (en) | 2001-08-07 |
| CN1277535C (zh) | 2006-10-04 |
| CZ296485B6 (cs) | 2006-03-15 |
| CA2398288A1 (en) | 2001-08-02 |
| EP1250132B1 (de) | 2005-03-30 |
| JP2003525223A (ja) | 2003-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434479T2 (de) | Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe | |
| DE69832108T2 (de) | Fenofibrathaltige Arzneizusammensetzung mit erhöhter Bioverfügbarkeit und Verfahren zu deren Herstellung | |
| DE60210315T2 (de) | Tamsulosin tabletten | |
| DE60004052T2 (de) | Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone | |
| DE69730314T2 (de) | Dosierungsform von ibuprofen | |
| AT394310B (de) | Verfahren zur herstellung lagerstabiler, schnellzerfallender pharmazeutischer wirkstoff-presslinge | |
| DE69802543T3 (de) | Verbesserte multipartikel-tablette mit schnellauflösbarkeit | |
| EP0607467B1 (de) | S(+)-Ibuprofen enthaltende Arzneimittel | |
| DE69434640T2 (de) | Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe | |
| AT392901B (de) | Verfahren zur herstellung einer granulaeren form mit verzoegerter freisetzung von pharmazeutisch wirksamen substanzen | |
| DE69820287T2 (de) | Pharmazeutische Zubereitung, die Chlodronat als Wirkstoff und silicifizierte mikrokristalline Cellulose als Exipienten umfasst | |
| EP0068191B1 (de) | Orale Dipyridamolformen | |
| DE69730834T2 (de) | Verfahren zur herstellung von festen oralen dosierungsformen von valsartan | |
| EP0582186B1 (de) | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung | |
| DE69923200T2 (de) | Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe | |
| EP1250132B1 (de) | Ibuprofen-wirkstoffzubereitung | |
| EP0173210A2 (de) | Pellet-Zubereitung | |
| EP0052076B1 (de) | Schnellzerfallende Arzneimittel-Presslinge | |
| WO2003030869A1 (de) | Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung | |
| DD292837A5 (de) | Verfahren zur herstellung von cholestyramin-tabletten | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| WO2012010669A2 (de) | Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer | |
| WO1994017793A1 (de) | Verfahren zur herstellung einer s-ibuprofen enthaltenden tablette | |
| DE19740983A1 (de) | Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten | |
| EP2585050A1 (de) | Silodosin-cyclodextrin einschlussverbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |